For more than 25 years, Myriad has led the way in genomics, molecular diagnostics, and the development of innovative products that transform patients’ lives.
Myriad developed the first molecular diagnostic test for breast cancer, BRACAnalysis®,
which became the standard of care for determining a person’s risk of developing hereditary cancers.
Which Test Makes Sense For You?
BRACAnalysis®
Breast | Ovarian
About 1 in 8 women in the US will develop breast cancer during their lives. In some cases, these cancers are due to an inherited gene mutation.¹
The BRACAnalysis ® genetic test assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.
Get This Test
COLARIS®
Colon | Endometrial | Ovarian
Lynch syndrome is among the most common hereditary cancer syndromes with 1 in every 300 people carrying a gene mutation associated with Lynch syndrome.²
The COLARIS® genetic test assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine (endometrial) cancer. COLARIS® detects disease-causing mutations in the MLH1, MSH2, EPCAM, MSH6, PMS2and MYH genes that are responsible for the majority of Lynch syndrome cases.
Get This Test
Myriad myRisk® Testing Kit
28-gene panel identifying elevated risk for 8 hereditary cancers
Breast | Ovarian | Gastric | Colorectal | Pancreatic | Melanoma | Prostate| Endometrial
Blending both genetic test status AND personal cancer family history, Myriad myRisk® hereditary cancer test represents the next generation of hereditary cancer risk testing. The Myriad myRisk® hereditary cancer test assesses multiple genes with syndromic overlap. That means we spend less time worrying about test selection and more time focusing on optimizing for medical management.
Studies have shown that testing with Myriad myRisk increases mutation detection between 40-50%.
- ✓ Save money and time
- ✓ Allow for earlier intervention
- ✓ Reduce false negative results
